(5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide
C68H82F3N13O12S2 — CID 166611797
Data last refreshed: (MolForge compound catalog, from PubChem)
About (5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide
(5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide (PubChem CID 166611797) has the molecular formula C68H82F3N13O12S2 and a molecular weight of 1394.61 g/mol. Its IUPAC name is (5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide.
Molecular Properties
| Compound Name | (5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide |
|---|---|
| PubChem CID | 166611797 |
| Molecular Formula | C68H82F3N13O12S2 |
| Molecular Weight | 1394.61 g/mol |
| Exact Mass | 1393.56 |
| IUPAC Name | (5R,8S,14S,17S,20S,26S,29S,35S)-35-(4-aminobutyl)-44-fluoro-26,29-bis[(5-fluoro-1H-indol-3-yl)methyl]-17-[(1R)-1-hydroxyethyl]-14-[(4-hydroxyphenyl)methyl]-8-methyl-7,13,16,19,25,28,31,34,37-nonaoxo-3,40-dithia-6,12,15,18,24,27,30,33,36-nonazatetracyclo[40.3.1.08,12.020,24]hexatetraconta-1(45),42(46),43-triene-5-carboxamide |
| SMILES | C[C@@H](O)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccc(F)cc23)NC(=O)[C@H](Cc2c[nH]c3ccc(F)cc23)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CCSCc2cc(F)cc(c2)CSC[C@@H](C(N)=O)NC(=O)[C@]2(C)CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC1=O |
| InChI | InChI=1S/C68H82F3N13O12S2/c1-37(85)59-64(93)80-53(26-38-9-13-46(86)14-10-38)66(95)84-21-6-18-68(84,2)67(96)81-55(60(73)89)36-98-35-40-23-39(24-45(71)25-40)34-97-22-17-57(87)77-51(7-3-4-19-72)61(90)76-33-58(88)78-52(27-41-31-74-49-15-11-43(69)29-47(41)49)62(91)79-54(65(94)83-20-5-8-56(83)63(92)82-59)28-42-32-75-50-16-12-44(70)30-48(42)50/h9-16,23-25,29-32,37,51-56,59,74-75,85-86H,3-8,17-22,26-28,33-36,72H2,1-2H3,(H2,73,89)(H,76,90)(H,77,87)(H,78,88)(H,79,91)(H,80,93)(H,81,96)(H,82,92)/t37-,51+,52+,53+,54+,55+,56+,59+,68+/m1/s1 |
| InChIKey | DSUVELDKXDKGHU-WPCSGHSJSA-N |
| XLogP | 2.76 |
| TPSA | 385.47 Ų |
| H-Bond Donors | 13 |
| H-Bond Acceptors | 15 |
| Rotatable Bonds | 12 |
| Heavy Atoms | 98 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1394.61 |
| LogP ≤ 5 | 2.76 |
| H-Bond Donors ≤ 5 | 13 |
| H-Bond Acceptors ≤ 10 | 15 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166611797 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.